In BC, most clinical emphasis is placed on a patient’s individual hormone receptor (HR) status (estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)) as well as the tumor proliferative index measured by Ki-67. Here, ESR1 is linked to breast cancer.